These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

477 related items for PubMed ID: 25077897

  • 41. Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
    Qu Y, Wu X, Yin Y, Yang Y, Ma D, Li H.
    J Exp Clin Cancer Res; 2014 Jun 17; 33(1):52. PubMed ID: 24939055
    [Abstract] [Full Text] [Related]

  • 42. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
    Park KS, Oh B, Lee MH, Nam KY, Jin HR, Yang H, Choi J, Kim SW, Lee DH.
    Cancer Lett; 2016 Mar 01; 372(1):75-81. PubMed ID: 26723875
    [Abstract] [Full Text] [Related]

  • 43. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor.
    Freeman DJ, Bush T, Ogbagabriel S, Belmontes B, Juan T, Plewa C, Van G, Johnson C, Radinsky R.
    Mol Cancer Ther; 2009 Jun 01; 8(6):1536-46. PubMed ID: 19509246
    [Abstract] [Full Text] [Related]

  • 44. The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells.
    Chen MC, Chen CH, Wang JC, Tsai AC, Liou JP, Pan SL, Teng CM.
    Cell Death Dis; 2013 Sep 19; 4(9):e810. PubMed ID: 24052078
    [Abstract] [Full Text] [Related]

  • 45. [Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].
    Han R, Wang X, Zhong D, Zhao J, Chen Z, Sun L, Wang J, Zhang J.
    Zhongguo Fei Ai Za Zhi; 2012 Dec 19; 15(12):689-93. PubMed ID: 23249714
    [Abstract] [Full Text] [Related]

  • 46. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
    Lv T, Li Z, Xu L, Zhang Y, Chen H, Gao Y.
    Acta Biomater; 2018 Aug 19; 76():257-274. PubMed ID: 29960010
    [Abstract] [Full Text] [Related]

  • 47. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
    Tong X, Tanino R, Sun R, Tsubata Y, Okimoto T, Takechi M, Isobe T.
    Respir Res; 2019 Dec 02; 20(1):270. PubMed ID: 31791326
    [Abstract] [Full Text] [Related]

  • 48. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type EGFR Family Members.
    Yan D, Parker RE, Wang X, Frye SV, Earp HS, DeRyckere D, Graham DK.
    Clin Cancer Res; 2018 Dec 15; 24(24):6523-6535. PubMed ID: 30194074
    [Abstract] [Full Text] [Related]

  • 49. Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer.
    Liu H, Lu J, Hua Y, Zhang P, Liang Z, Ruan L, Lian C, Shi H, Chen K, Tu Z.
    Cell Death Dis; 2015 Jan 15; 6(1):e1595. PubMed ID: 25590805
    [Abstract] [Full Text] [Related]

  • 50. Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models.
    Proia DA, Sang J, He S, Smith DL, Sequeira M, Zhang C, Liu Y, Ye S, Zhou D, Blackman RK, Foley KP, Koya K, Wada Y.
    Invest New Drugs; 2012 Dec 15; 30(6):2201-9. PubMed ID: 22227828
    [Abstract] [Full Text] [Related]

  • 51. Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes.
    Friedland JC, Smith DL, Sang J, Acquaviva J, He S, Zhang C, Proia DA.
    Invest New Drugs; 2014 Feb 15; 32(1):14-24. PubMed ID: 23686707
    [Abstract] [Full Text] [Related]

  • 52. Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines.
    Cavazzoni A, Alfieri RR, Cretella D, Saccani F, Ampollini L, Galetti M, Quaini F, Graiani G, Madeddu D, Mozzoni P, Galvani E, La Monica S, Bonelli M, Fumarola C, Mutti A, Carbognani P, Tiseo M, Barocelli E, Petronini PG, Ardizzoni A.
    Mol Cancer; 2012 Dec 12; 11():91. PubMed ID: 23234355
    [Abstract] [Full Text] [Related]

  • 53. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
    Chen Y, Wu J, Yan H, Cheng Y, Wang Y, Yang Y, Deng M, Che X, Hou K, Qu X, Zou D, Liu Y, Zhang Y, Hu X.
    Pharmacol Res; 2020 Sep 12; 159():105007. PubMed ID: 32561477
    [Abstract] [Full Text] [Related]

  • 54. Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression.
    Tanaka H, Sakagami H, Kaneko N, Konagai S, Yamamoto H, Matsuya T, Yuri M, Yamanaka Y, Mori M, Takeuchi M, Koshio H, Hirano M, Kuromitsu S.
    Mol Cancer Ther; 2019 Aug 12; 18(8):1366-1373. PubMed ID: 31092564
    [Abstract] [Full Text] [Related]

  • 55. Molecular profiling of afatinib-resistant non-small cell lung cancer cells in vivo derived from mice.
    Chung CT, Yeh KC, Lee CH, Chen YY, Ho PJ, Chang KY, Chen CH, Lai YK, Chen CT.
    Pharmacol Res; 2020 Nov 12; 161():105183. PubMed ID: 32896579
    [Abstract] [Full Text] [Related]

  • 56. The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib.
    Zou Y, Ling YH, Sironi J, Schwartz EL, Perez-Soler R, Piperdi B.
    J Thorac Oncol; 2013 Jun 12; 8(6):693-702. PubMed ID: 23575415
    [Abstract] [Full Text] [Related]

  • 57. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.
    Zheng Q, Dong H, Mo J, Zhang Y, Huang J, Ouyang S, Shi S, Zhu K, Qu X, Hu W, Liu P, Wang Y, Zhang X.
    Theranostics; 2021 Jun 12; 11(2):824-840. PubMed ID: 33391507
    [Abstract] [Full Text] [Related]

  • 58. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
    Sano Y, Hashimoto E, Nakatani N, Abe M, Satoh Y, Sakata K, Fujii T, Fujimoto-Ouchi K, Sugimoto M, Nagahashi S, Aoki M, Motegi H, Sasaki E, Yatabe Y.
    Mol Cancer Ther; 2015 Feb 12; 14(2):533-41. PubMed ID: 25522765
    [Abstract] [Full Text] [Related]

  • 59. EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer.
    Amato KR, Wang S, Tan L, Hastings AK, Song W, Lovly CM, Meador CB, Ye F, Lu P, Balko JM, Colvin DC, Cates JM, Pao W, Gray NS, Chen J.
    Cancer Res; 2016 Jan 15; 76(2):305-18. PubMed ID: 26744526
    [Abstract] [Full Text] [Related]

  • 60. Clathrin-mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild-type EGFR non-small cell lung cancer.
    Kim B, Park YS, Sung JS, Lee JW, Lee SB, Kim YH.
    Cancer Med; 2021 Jan 15; 10(1):372-385. PubMed ID: 33314735
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.